Furthermore, we observed a twofold increase in the number of CD4+TRM cells and a sixfold increase in the number of CD8+TRM cells in the skin at the tumor rechallenge sites compared to the concurrent accumulation of many activated CD69+CD103-T cells into the skin prior to the rechallenge (Fig. 4F,G). The gene discussed is CD4; the disease is neoplasm.